Defence Therapeutics Inc (TSE:DTC) has released an update.
Defence Therapeutics Inc. has announced the therapeutic effectiveness of its ARM-002 anti-cancer vaccine, which shows significant promise when paired with an anti-PD-1 immune-checkpoint inhibitor in treating melanoma. This second-generation vaccine, enhanced by AccuTOX technology, demonstrates potent antigen presentation and requires lower doses than its predecessor. The company is expanding its testing to include various ‘hard-to-treat’ cancers, aiming to establish its viability for Phase I clinical trials.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
